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Abstract
This paper proposes a novel complementary approach to evaluate the public
health benefits of air pollution control, where the joint impact on individuals’
quality and length of life is fully quantified using Markov modelling. A Markov
model which captures, for the first time: (i) air pollution’s influence on popula-
tion individuals’ quality of life and life expectancy at baseline and (ii) dynamics
in individuals’ susceptibility to air pollution exposure, is developed. In order to
represent the body of epidemiological evidence on the cardio-respiratory effects
of long-term exposure to fine particulate air pollution, the model is structured
around three diseases: chronic obstructive pulmonary disease, coronary heart
disease and lung cancer. Application of the model provides the first estimates of
age and gender-specific quality-adjusted life years (QALY) gains from air qual-
ity improvement in the UK. Reducing mean PM2.5 concentrations by 1µg/m
3
in London and in England and Wales is expected to yield more than 63,000 and
540,000 QALYs respectively, to adults aged 40 and above over their remaining
lifetime, discounting at 3.5% p.a. At a WTP value for a QALY of £65,000,
which is in line with recommendations for the UK, the expected discounted
monetary benefit of the intervention amounts to £4 billion in London and £34
billion in England and Wales.
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1. Introduction
In recent years, as the body of evidence on the adverse health effects of
air pollution has kept on growing, policy-makers have been increasingly under5
pressure to take action but also, to ensure that further air quality efforts are
worthwhile (HEI, 2003). This has spurred several ex ante economic evaluations
of large-scale regulatory interventions of air pollution control (e.g. Revisions
to the National Ambient Air Quality Standards for Particulate Matter in the
US (US EPA, 2012), Clear Air for Europe (Holland et al., 2005), revisions of10
the E.U. Gothenburg Protocol (Holland et al., 2011)) and of a large number of
hypothetical scenarios of air pollution reduction on a local, national or global
scale (Bell et al., 2011).
The mortality effects of reducing air pollution are traditionally quantified
in premature deaths avoided or life expectancy gains using life-tables, whereas15
morbidity impacts are measured in counts of avoided morbid cases obtained by
health impact functions (Medina et al., 2013). In addition to being quantified
with a static quantification tool, the morbidity effects considered are primar-
ily acute (e.g. hospitalizations, respiratory exacerbations) following short-term
variations in air pollution exposure (WHO, 2013). Consequently, the long-term20
quality of life impacts associated with a reduction in chronic morbidity follow-
ing a sustained decrement in ambient levels of air pollution, have largely been
ignored.
This paper therefore proposes a novel complementary approach to evaluate
the public health benefits from air pollution control, where the joint impact on25
individuals’ quality and length of life, measured in quality-adjusted life years
(QALYs), is fully quantified using Markov modelling.
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The QALY combines morbidity and mortality effects into a single index and
is obtained by multiplying the period of time spent in a given health state by
health-related quality of life (HRQoL) weights associated with that state (Gold30
et al., 2002). The benefits of using this metric in environmental health policy in-
clude the ability to compare health outcomes from different policies, to consider
another dimension than quantity of life and to encompass individuals’ prefer-
ences between alternative health states (Ponce et al., 2001). In addition, since
the QALY routinely supports health care resources allocation (Drummond et al.,35
2005), its use in the assessment of air pollution control interventions can sup-
port the comparison with health care interventions, for which cost-effectiveness
decision rules are typically in place.
Whilst there have been a number of attempts to estimate the QALY gain
from air pollution reduction, they all suffer from two main limitations. To40
put them into context, it should be noted that air pollution can affect indi-
viduals’ health via three main pathways to effect: (A) development of chronic
conditions that reduce life expectancy and quality of life but are unrelated to
the timing of death; (B) death advancement, following acute exposure, in frail
individuals whose frailty is unrelated to air pollution exposure; and (C) develop-45
ment of chronic conditions leading to frailty combined with death advancement
following acute exposure (Ku¨nzli et al., 2001). Correct quantification of the
QALY impacts of air pollution exposure requires to jointly consider these three
pathways to effect, in particular to avoid under-estimating the life expectancy
and quality of life loss associated with the premature deaths of individuals in50
pathway C (Hubbell, 2006). This challenging issue, however, has not yet been
adequately addressed. Using the life-table method, Coyle et al. (2003) simply
applied HRQoL weights for the general population to the life year gains from a
lower risk of premature mortality and completely ignored the quality of life gains
associated with reduced morbidity. Cohen et al. (2003) used a similar method55
but assumed that all the individuals who die prematurely from air pollution suf-
fered from a preexisting coronary or respiratory condition, without accounting
for air pollution’s role in driving a subset of them to such health state. Such an
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approach further contributed to underestimating the QALY gain of air pollu-
tion control. Whilst Hubbell (2006) partly accounted for air pollution’s impact60
on quality of life via the development of chronic bronchitis, he did not use the
resulting level of quality of life as a baseline to adjust the life years gains from
a reduced mortality risk. This use of a double baseline of HRQoL weights to
assess respectively morbidity and mortality effects - an approach also used by
the US EPA (US EPA, 2006) to estimate MILYs - no longer allows a linear65
substitution between quality and quantity of life and thus, clearly departs from
the QALY.
Second, none of the above-mentioned studies accounted for the fact that
individuals suffering from a compromised health condition are expected to be
more susceptible to air pollution exposure than healthier individuals (Peled,70
2011; Sacks et al., 2011; US EPA, 2009). Health-related heterogeneity in sus-
ceptibility to air pollution drives the distribution of impacts among population
subgroups stratified by health condition. It is therefore key to accurately adjust
life expectancy effects with HRQoL weights.
In contrast, by simulating individuals’ health trajectories over time to and75
from a set of mutually exclusive and exhaustive health states, the proposed
Markov modelling-based approach provides two core advantages to estimate the
QALY gain from air pollution abatement. First, individuals’ quality of life and
life expectancies are no longer treated as exogenous parameters. Instead, they
are endogenously determined as a function of individuals’ current health con-80
ditions, where the influence of air pollution in driving them to their respective
states of health is fully accounted for. Second, individuals’ change in suscepti-
bility to air pollution exposure over time, as a consequence of a degraded health
condition that may or may not be associated with air pollution exposure, is
encompassed. Thanks to these two features, the lifetime impact of chronic air85
pollution exposure on individuals’ quality and length of life is fully captured.
In addition, the proposed approach can quantify both the health care savings
from a reduced occurrence of morbidity events, as well as the health care costs
from extending the lives of individuals with chronic medical conditions. As a
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consequence, the total health care budget impact of reducing air pollution can90
be evaluated.
The objective of this paper is threefold. It aims to: (i) translate the rich
body of epidemiological evidence on the adverse health effects of fine particulate
pollution into chronic conditions associated with well-documented effects on
life expectancy, quality of life and health care costs; (ii) construct a Markov95
model that captures the main characteristics of these chronic conditions and
encompasses the most relevant epidemiological evidence; (iii) apply the model
to quantify, for the first time, age and gender-specific QALY gains and total
health care resource impacts of reducing PM2.5 concentrations in England and
Wales and in London respectively.100
2. Materials and methods
2.1. Scope of analysis
105
The present analysis aims to quantify the lifetime impacts on life expectancy,
quality of life and health care resources of reducing population exposure to
PM2.5, i.e. particulate matter smaller than 2.5µm in aerodynamic diameter,
which is considered to adversely affect population health more than any other
air pollutant (WHO, 2014).110
Given the chosen timescale, only chronic health effects from long-term expo-
sure are modelled. Consequently, short-term quality of life effects from morbid
events triggered by acute exposure, such as respiratory exacerbations for in-
stance, are not presently taken into account1. The latter are, however, not
expected to drive levels of quality of life over a lifetime.115
1It should be noted that the life-shortening effect of acute exposure is captured in the
overall change in death risk associated with chronic exposure (Ku¨nzli et al., 2001).
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Although children are expected to be particularly susceptible to air pollu-
tion (Peled, 2011), documented adverse effects primarily pertain to respiratory
exacerbations following acute exposure, which are outside the present scope of
analysis, or to subclinical respiratory conditions (e.g. reduced lung growth)
which are not well characterised with incidence and prevalence statistics. On120
these grounds, the present analysis focuses on chronic health impacts experi-
enced in adulthood. Importantly, since chronic respiratory impacts in adults
partly derive from the worsening over time of subclinical conditions developed
since childhood (Eisner et al., 2010; Peled, 2011), the long-term damaging im-
pact of chronic PM2.5 exposure on children’s lung development should to some125
extent, be encompassed in the analysis.
2.2. Main chronic health impacts in adults
130
As explained in section 1, the life shortening impact of particulate air pollu-
tion exposure is expected to be greatly mediated via the increase in the risks of
developing chronic conditions. Epidemiological studies suggest a positive associ-
ation between long-term exposure to fine particulate air pollution and coronary
atherosclerosis (Adar et al., 2013), myocardial infarction (Lipsett et al., 2011),135
coronary re-vascularization (Miller et al., 2007) and acute and sub-acute forms of
coronary heart disease (Cesaroni et al., 2014). Whilst particulate matter (PM)
exposure has also been associated with stroke (Miller et al., 2007), to date the
overall evidence of association with regards to long-term exposure remains weak
(Brook et al., 2010). Based on this body of evidence and constraints in terms of140
required population statistics, the impacts of chronic air pollution exposure on
the cardiovascular system were modelled using coronary heart disease (CHD) -
ICD-10 I20-I25 - as health endpoint.
A number of studies have also shown positive associations between PM ex-
posure and respiratory symptoms (Schindler et al., 2009; Abbey et al., 1995) as145
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well as lung function decrements (Downs et al., 2007), all of which are associ-
ated with chronic obstructive pulmonary disease (COPD). Although the body
of evidence linking PM exposure and COPD development remains incomplete
(Schikowski et al., 2013), such association is likely as reduced pulmonary growth
in childhood and adolescence - for which the link with PM exposure is now es-150
tablished - increases the incidence of COPD later in life (Eisner et al., 2010).
The COPD disease pathway (ICD-10 J40-J44) was therefore chosen to model
the chronic respiratory impacts of PM exposure.
Lung cancer (ICD-C33-34), which has repeatedly been found to be associ-
ated with chronic PM exposure (Hamra et al., 2014), was considered as a third155
morbidity endpoint.
2.3. Model structure
2.3.1. Markov models: key features160
Discrete time Markov models are extensively described in Sonnerberg and
Beck (1993). They have two key structural components: (i) mutually exclusive
and exhaustive health states and (ii) transition probabilities (TP) which rep-
resent the probability of transiting between health states during a cycle “c”,165
conditional on being in a given health state in cycle “c-1”. TP can, however,
be conditional on past health history using tunnel states in which individuals
can only spend one cycle. TP are typically stratified by age and gender and are
time-dependent.
170
2.3.2. Disease pathways
The model was built around three disease pathways - one for each chronic
morbid condition defined in section 2.2 - alongside the states “dead” and “healthy”,
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where the latter represents a health state exempt of any of the three conditions.175
As the analysis timescale was the individual’s lifetime, the cycle period was set
to one year. Due to data gaps pertaining to co-morbidity risks, the model as-
sumed competitive risk between the three diseases, i.e. one individual cannot
suffer from two or more conditions at the same time. In addition, each disease
pathway was underpinned by the following structural assumptions:180
COPD. As health care cost, quality of life decrements and mortality risk greatly
depend on the level of airflow obstruction, the COPD pathway was structured
around the four severity stages: GOLD 1 to GOLD 4, defined by the Global ini-
tiative for chronic Obstructive Lung Disease (GOLD, 2014). Although COPD is
treatable, it is not reversible and typically slowly worsens over time. In addition,185
it is often diagnosed in late stages (GOLD, 2014). To reflect these characteris-
tics, the COPD pathway was designed as unidirectional - i.e. transitions back
to “healthy” or to a less severe state were not permitted - and upon entry into
the disease pathway, no jump of severity stage was allowed. By contrast, to
reflect the reality of late diagnosis, transitions from the state “healthy” to the190
first three severity levels of the disease were allowed (see Figure 1).
CHD. Although CHD also has different levels of severity that will influence
quality of life and life expectancy, in the absence of a widely accepted classifica-
tion of the disease by severity stages, the CHD pathway was composed of only
one state. The CHD pathway was also designed as unidirectional, since CHD is195
a chronic condition that requires long-lasting disease management.
Lung cancer. Whilst 5-year lung cancer survivors remain at risk of cancer re-
currence, most recurrences (around 80%) occur about 2 years after surgical
resection (Maeda et al., 2010). Consequently, it was assumed that after 5 years
alive with the condition, individuals would transit back to the state “healthy”,200
from where they would face the same risks of adverse health events and enjoy
the same quality of life as “healthy” individuals of same age and gender. The
disease pathway was structured around five tunnel states, in order to differenti-
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ate lung cancer patients and their survival probabilities according to the period
of time during which they had been suffering from the disease.205
2.3.3. Intervention arm and risk reduction estimates
To evaluate an intervention of air pollution reduction, the model requires:
a “baseline” arm populated with baseline TP and (ii) an “intervention” arm210
in which baseline TP are combined with risk reduction estimates (RRE). The
latter are epidemiological risk estimates scaled to the decrement in exposure
associated with the intervention under evaluation.
In addition to morbidity RRE that represent the decrease in the risks of
developing lung cancer, CHD and COPD, mortality RRE were applied in the215
“intervention” arm so that the total life expectancy gain from air pollution
reduction, mediated by the three pathways to effect described in section 1,
would be captured.
In line with WHO (2013)’s recommendations, mortality RRE pertaining to
all causes of death were used. The specificity of the present model, however,220
is that it relies on mortality RRE stratified by health status, i.e. conditional
on having CHD or COPD or LC or on being “healthy”. Such an approach is
key to: (i) capture health-related differential susceptibility to air pollution, by
allowing for a different magnitude of death risk reduction according to whether
individuals are frail or not; and (ii) avoid double-counting the life expectancy225
gains from the reduced risk of developing a chronic cardio-respiratory condition,
which are already encompassed via the application of morbidity RRE in the
model. It follows that the change in death risk that was applied to “healthy”
individuals pertains to all the other causes of death than the three modelled.
The change in death risk in individuals who had developed COPD and CHD,230
be it due to air pollution exposure or for any other reasons, was informed by
Zanobetti et al. (2008) and Tonne and Wilkinson (2013)’s respective estimates
of excess risk of all-cause mortality associated with chronic PM exposure in
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these two populations subgroups. Zanobetti et al. (2008) results, however, were
based on COPD patients who were aged above 65 years old and had been235
identified using hospital discharge data. As the risk of hospital admission for
COPD greatly increases with disease severity, in order to limit study results
extrapolation, the study’s risk estimate was applied only to individuals aged 65
and above if they were in GOLD 3 or 4 states. Individuals with COPD in GOLD
stages 1 and 2 or, in GOLD stages 3 and 4 but aged below 65, were instead240
assumed to face the same reduction in mortality risk as the general population.
Similarly, Tonne and Wilkinson (2013)’s study was based on patients above
25 years of age admitted to hospital following acute coronary syndrome (ACS).
ACS reflects a more severe health condition than CHD as a whole. Since the risk
of ACS strongly increases with age (Simms et al., 2012), Tonne and Wilkinson245
(2013)’s risk estimate was applied to individuals suffering from CHD only if they
were aged 75 or above. Individuals with CHD aged below 75 were assumed to
face the same reduction in mortality risk as the general population.
Finally, since lung cancer is associated with a high risk of death, the impact
of PM2.5 exposure was restricted to disease development (RREc). In other250
words, reducing air pollution was assumed to have no impact on the mortality
risk of individuals with lung cancer.
RRE and the TP they apply to are presented in Table 1. Risk estimates
were preferably taken from meta-analyses to decrease parameter uncertainty.
They were obtained from studies undertaken in developed countries that are255
characterised by PM2.5 concentrations ranging from about 7 to 35 µg/m
3, for
which linearity in health impacts and absence of threshold to effects has typically
been found (Lepeule et al., 2012; Crouse et al., 2012; Krewski et al., 2009).
This implies that within the above concentrations range: (i) estimates of health
effects for a different level of pollution reduction may be obtained to a very good260
approximation by proportional scaling of the results obtained for a 1 µg/m3
reduction; (ii) RRE can be derived from risk estimates - typically expressed
per 10µg/m3 increment - using logarithmic multiplicative scaling. RRE values
provided in Table 1 are expressed for a 1 µg/m3 decrement.
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Figure 1 represents the structure of the intervention arm of the model, where
ovals represent health states and arrows represent the allowed transitions be-
tween them. Dotted arrows represent RRE-adjusted transitions, i.e. transitions
for which the underlying risk of event is reduced under pollution reduction,
whereas full arrows represent transitions for which the underlying risk of event270
is assumed to be unchanged under intervention.
Figure 1: Diagram of the intervention arm of developed Markov model.
Abbreviations: COPD: chronic obstructive pulmonary disease; CHD: coronary heart disease;
LC: lung cancer: Yr: year. Risk reduction estimates RREa, ...g are defined in Table 1.
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Parameter Transition Pop. Risk Reduction Estimates (RRE)
Name Probability age Risk Estimates Mean (95%CI)
PX,Y (a) Definition Source △PM2.5 = −1µg/m
3
RREa PH,COPDi All ORDev.COPD Schikowski et al. (2014)(b) 0.988 (0.918-1.065)
i=GOLD1,..., 3
RREb PH,CHD All HRDev.CHD Cesaroni et al. (2014) (b) 0.976 (0.949-1.004)
RREc PH,LC All HRDev.LC Hamra et al. (2014)(b) 0.985 (0.980-0.991)
RREd PCOPDi,D All HRDeathAC Hoek et al. (2013)(b) 0.993 (0.991-0.995)
i=GOLD1,...,2
RREe PCOPDi,D < 65 HRDeathAC Hoek et al. (2013)(b) 0.993 (0.991-0.995)
i=GOLD3,...,4 ≥ 65 HRDeathAC|COPD Zanobetti et al. (2008)(c) 0.980 (0.976-0.984)
RREf PCHD,D < 75 HRDeathAC Hoek et al. (2013)(b) 0.993 (0.991-0.995)
≥ 75 HRDeathAC|CHD Tonne and Wilkinson (2013) 0.982 (0.968-0.996)
RREg PH,D All HRDeathAOC|H Pope III et al. (2002) 0.999 (0.994-1.005)
Table 1: Risk reduction estimates used to parametrise the intervention arm.
Abbreviations: PX,Y : age and gender-specific annual probability of developing disease/
experiencing event “Y”, conditional on being in health state “X”; Dev. = developing; COPD
= chronic obstructive pulmonary disease; CHD = coronary heart disease; LC = lung cancer;
H = healthy; D = dead; HR = hazard ratio; HRY |X : hazard ratio of event “Y” in
population with health condition “X”; OR = odd ratio; AC = all causes; AOC = all other
causes than COPD, CHD and LC.
(a) As TP are non-linear function of time, their multiplication with RRE is carried out on
the transition rate scale. The obtained product is then converted back to probability to
parameterise the intervention arm.
(b) Meta-analysis study.
(c) Results based on PM10 data.
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2.4. Parameterising the model for UK case study275
2.4.1. Case study definition
The intervention is an hypothetical sustained and immediate 1µg/m3 re-
duction in mean ambient concentrations of PM2.5 in England and Wales or in280
London only. This would represent a 9% and 7% reduction of respective current
concentration levels (COMEAP, 2010), which is in line with the UK Air Quality
Strategy’s reduction target2 (DEFRA, 2007).
The target population was defined as the current adult population aged 40
to 90, living in England and Wales (or in London only for London results)285
and followed until death, with a cut-off at 100 years old. The analysis time
horizon is therefore 60 years. Whilst WHO (2013) recently recommended to
apply mortality risk estimates to adults aged 30 and over, the restriction to
individuals aged 40 and above was driven by the availability of routine disease
incidence and prevalence statistics. Since the risk of mortality below 40 remains290
low, this restriction is not expected to lead to a substantial underestimation of
the health benefits of air pollution control.
The lag between exposure decrement and health risks reduction was assumed
to follow the 20-year distributed lag developed and currently used by the US
EPA: 30% risk reduction in year 1, an additional 12.5% every year between year295
2 to year 5 and the final 20% being phased in gradually over year 6 to year 20
(US EPA, 2010). However, since the US EPA’s lag was developed to evaluate
the change in the risk of all-cause mortality, sensitivity analysis using different
lags for morbid endpoints will be performed. For comparability with health
care interventions, a discount rate of 3.5% was applied to health care costs and300
QALY gains, in line with guidelines for England and Wales (NICE, 2013).
2Reduction of PM2.5 concentrations at all locations, including a 15% reduction at all urban
locations, by 2020.
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2.4.2. Population modelling
Modelling of currently alive adults aged 40 to 90 years old, was based on a305
total of 102 age and gender-specific cohorts of 1,000 individuals each. Results
were then re-scaled to the populations of England and Wales and London, in
line with their respective age and gender-distributions (2011 census). The model
was built and evaluated in MATLAB.
310
2.4.3. Baseline Transition Probabilities (TP)
Data for England and Wales, or alternatively for the UK were used (i.e. no
London-specific data was used). Disease prevalence data was used to distribute
each of the 102 cohorts into the model’s states at cycle 0, whereas annual disease315
incidence statistics informed cohorts’ transitions from the state “healthy” to
each disease state during each yearly cycle. Individuals were assumed to move
between states at mid-cycle.
For CHD and lung cancer, incidence and prevalence data provided by the
UK Clinical Practice Research Datalink were obtained from the open-access320
model DYNAMO-HIA3.
Parametrisation of the COPD pathway was slightly more complex, owing
to the need to account for disease progression at patient-level as well as se-
vere under-diagnosis of the disease, whereby less than a third of individuals
with probable airflow limitation reported a doctor-diagnosis of COPD in 2010325
Health Survey for England (Aresu et al., 2011). COPD progression probabil-
ities were derived by combining annual progression probabilities stratified by
smoking status provided by Atsou et al. (2011) with data on the distribution
3http://www.dynamo-hia.eu
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of COPD patients in England by smoking status from Shahab et al. (2006).
This approach was justified by the lack of strong evidence to date that suggests330
that smoking could impact upon individuals’ biological response to air pollution
exposure (Laurent et al., 2007). Death probabilities associated to the COPD
pathway were calculated using GOLD-stratified hazard ratios of excess mortal-
ity in COPD patients estimated by Mannino et al. (2006). The incidence of
the disease by severity stage was estimated by combining disease progression335
and GOLD-stratified death risks with estimates of the disease “true” under-
lying prevalence provided by the UK Department of Health (2010). Incidence
estimation results are provided in Appendix A.
Mortality statistics for the general population were obtained from the UK
Office for National Statistics (ONS, 2013) and reflect the assumption of compet-340
itive risk that underpins the model (see section 2.3.2). The probability of death
conditional on having CHD was derived from life-table computations, assuming
suffering from the condition did not affect the risk of death from all other causes
than CHD. The probabilities of death in lung cancer patients were based on age
and gender-specific ratios of relative survival at 1 and 5 years since diagnosis345
(ONS, 2011). Estimation of relative survival ratios at the other time points (i.e.
at 2, 3 and 4 years) was carried out by fitting a Weibull survival function to the
data.
2.4.4. HRQoL weights350
The EuroQol five dimensional instrument (EQ-5D), which is the most com-
monly used HRQoL metric for cost-effectiveness analysis (De Smedt et al., 2014)
was chosen to express the quality of life associated with each health state.
Age and gender-specific HRQoL scores experienced by “healthy” individuals355
were obtained from Kind et al. (1999). HRQoL scores associated with each
condition are presented in Table 2 (left-hand side). HRQoL weights applied to
each condition were upper-bounded by the age and gender-matched scores of
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“healthy” individuals. Scores for COPD (by GOLD stages) and lung cancer
were taken from meta-analyses (Pickard et al., 2008; Sturza, 2010) and CHD360
scores were based on a very large patient population size (n=7,242) as part of
the EUROASPIRE III study (De Smedt et al., 2014).
The HRQoL score for lung cancer was based on results for non-small cell
cancer, which accounts for about 90% of all cases of cancer in England (Riaz
et al., 2012). The final HRQoL score was obtained by weighting HRQoL results365
for metastatic and non-metastatic non-small cell cancer by respectively 75% and
25%, based on the fact that 75% of non-small cell cancers are detected at an
advanced stage (NHSC, 2010).
2.4.5. Health care costs370
“Healthy” individuals were assumed not to generate any health care cost.
The average annual health care cost per patient in each condition is provided
in Table 2 (right-hand side). Costs were inflated to 2013 prices, based on the
hospital and community services’ inflation index for the UK NHS (PSSRU,375
2013).
In the absence of UK specific data, COPD costs stratified by GOLD stage
were based on a Swedish study (Jansson et al., 2013). The average annual cost
of a CHD patient was obtained by scaling the total annual cost of CHD in the
UK (£1.8 billion as of 2009, Nichols et al., 2012), to the number of CHD patients380
registered in the UK the same year (n= 2,330,277, British Heart Foundation,
2010). While the obtained annual cost per patient is low (£836), it was applied
from condition onset until death.
The annual cost of a lung cancer patient was provided by the National Cancer
Research Institute (NCRI, 2012), based on patients who have been diagnosed385
with cancer and are still alive. This includes newly diagnosed individuals and
individuals with stable disease or considered to be cured who are being followed-
up.
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HRQoL scores (EQ-5D) Mean annual cost
Age Severity Value (SE) / patient (2013 prices)
COPD All GOLD 1 0.74 (0.064) £249
GOLD 2 0.74 (0.043) £951
GOLD 3 0.69 (0.046) £2,033
GOLD 4 0.61 (0.084) £4,943
source: Pickard et al. (2008) source: Jansson et al. (2013)(a)
CHD ≤ 40 All 0.85 (0.069) £836
50-69 0.80 (0.079)
≥ 70 0.73 (0.059)
source: De Smedt et al. (2014) source: Nichols et al. (2012)
and British Heart Foundation (2010)
Lung All Non-metastatic 0.85 (0.074) £9,283
cancer Metastatic 0.57 (0.067)
source: Sturza (2010) source: NCRI (2012)
Table 2: Condition-specific HRQOL and health care costs.
(a) Converted in GBP using the average EUR/GBP exchange rate for 2013.
2.5. Sensitivity analyses390
Joint-uncertainty in a subset of parameters was handled probabilistically
by fitting lognormal distributions to risk estimates and beta distributions to
HRQoL scores (Briggs et al., 2006) and by performing Monte Carlo simulations
(10,000 draws). In addition, the sensitivity of results to discount rate and to395
lags in risk reduction was evaluated.
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2.6. Summary of assumptions
In order to point out potential biases associated with the model and its
application to the UK case study, a list of the main assumptions/limitations is400
provided in Table 3.
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Limitations expected to led to a moderate under-estimation of impacts
Case study:
- The target population is a static adult population aged 40 and above
Nature of effects captured in the model:
- Adverse effects in children are not encompassed (a)
- Quality of life effects from acute exposure are not captured
Model structure:
- Competitive risks between each three diseases is assumed
Limitations for which the direction of the potential bias is unclear
Model parameterisation:
- All-cause mortality RRE applied to individuals with CHD or COPD are based on single study
results, as opposed to meta-analyses
- For individuals with CHD or COPD, the use of all-cause mortality RRE does not exactly
match with the baseline probability of death of these individuals, because of the competitive
risk assumption (c)
- Correct estimation of the total life expectancy gain from air pollution reduction requires
valid baseline: (i) incidence of the three life-shortening conditions modelled (b) and
(ii) death risks stratified by health status
Table 3: Model limitations and expected direction of potential biases.
(a) Air pollution deleterious effects on children lung development are nevertheless expected to
be partially encompassed in the excess risk of developing COPD in adulthood.
(b) This prompted the estimation of the “true” underlying incidence of COPD, in order to
address the fact that this disease is severely under-diagnosed (see section 2.4.3)
(c) This is not an issue for “healthy” individuals or for those with lung cancer since the change
in death risk that was applied to “healthy” individuals pertains to all the other causes of death
than the three modelled and for those with lung cancer, no PM-related excess death risk was
applied.
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3. Results
3.1. Total QALY gain, health care resource impact and monetary benefit of in-405
tervention
Detailed summary results are provided in Table 4. Reducing mean PM2.5
concentrations by 1µg/m3 is expected to generate more than 63,000 QALYs
in London and 540,000 QALYs in England and Wales, among adults currently410
aged 40 and above over their remaining lifetime, discounting at 3.5% p.a.
The total net health care resource impact of the intervention, which corre-
sponds to the health care savings from a reduction in cases of CHD, COPD and
lung cancer, net of the health care costs from extending the lives of individuals
with a chronic cardio-respiratory condition4, is slightly cost increasing. It ac-415
counts for respectively £24 million in London and £263 million in England and
Wales.
In England, health care costs to the National Health Service can be expressed
as QALY losses using an estimate of the NHS expenditure required to deliver
one QALY. The latter was recently estimated at £13,000/QALY (Claxton et al.,420
2013). Based on this estimate, the QALY loss equivalent from net health care
costs accounts for 2.8% and 3.7% of the health benefits expected to be generated
by the intervention in London and in England and Wales respectively.
If the intervention is expected to be funded by raising new tax revenue,
it will displace private consumption and consequently, the population health425
benefits it generates should be monetized based on the consumption value of
a QALY. The UK Department of Health recommends to use a willingness to
pay (WTP) value of a QALY of £60,000 in 2009 prices (Glover and Henderson,
2010). In addition, Ryen and Svensson (2014)’s recent review of WTP values for
4It should be reminded that the intervention is not expected to impact upon the life
expectancy of individuals with lung cancer (see section 2.3.3).
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a QALY found a trimmed mean estimate of e 74,159 (2010 prices), with most430
estimates coming from European and US studies. At a value of £65,000/QALY,
which approximately corresponds to the two above cited values in GBP and
2013 prices, the intervention’s discounted monetized benefit over the 60-year
time horizon amounts to respectively £4 billion in London and £34 billion in
England and Wales.435
London England & Wales
Target population size (a) 3,215,975 27,273,400
QALY gain (b) 63,293 541,217
Net health care costs (c) £24 million £263 million
QALY loss equivalent (d) 1,825 20,219
Net QALY gain £61,467 £520,998
Total monetary benefit (e) £3,995 million £33,865 million
Table 4: Total health gain, health care resource impact and monetary benefit of reducing
ambient PM2.5 concentrations in the UK by 1µg/m3.
(a) Currently alive adults aged 40 to 90 years old.
(b) 60-year time horizon, applying a discount rate of 3.5 % p.a.
(c) Savings from a reduction in cases of CHD, COPD and lung cancer, net of costs from
extending the lives of individuals with a chronic cardio-respiratory condition.
(d) Using a value of £13,000/QALY as the shadow price of the NHS budget constraint.
(e) Using £65,000/QALY as the consumption value of a QALY.
3.2. QALDays and health care costs distributions by age and gender
Figure 2A depicts the expected quality-adjusted life day (QALD) gain per440
person associated with the intervention over his/her remaining lifetime. Al-
though health gain cumulates over time, due to discounting, the main ben-
eficiaries of the intervention are not the youngest individuals but those aged
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around 65 years old. Indeed, as the risk of experiencing adverse health events
increases with age, young individuals are expected to benefit from the interven-445
tion much later in the future than older individuals. Sensitivity analysis of the
age-distribution of health gain to the discount rate is provided in Appendix D.
Figure 2A shows the presence of a substantial gender-gap in health gain,
especially among young age groups, with the average QALD gain enjoyed by
40-year old men being nearly a third (28%) higher than the gain accruing to450
their female counterparts. This gap reflects gender-differences in baseline risks
of adverse health events, whereby men aged between 40 to 70 in the UK are
on average twice more likely to develop CHD and 60% more likely to die from
all causes than women. Whilst gender-differences in baseline health risks do
persist at older ages, there are substantially smaller. In addition, since women455
face a lower death risk, they are expected to enjoy the intervention’s benefit for
a slightly longer time period than men. As a consequence, the gender-gap in
health gain is a decreasing function of individuals age.
Figure 2B represents the expected health care cost impact of the intervention
per person (gender average). For individuals aged 53 and above, the health460
care savings from reducing their lifetime risk of developing COPD, CHD and
lung cancer are on average, more than compensated by the health care costs
associated with extending the lives of those with a chronic cardiac or respiratory
condition. It should be underlined that the latter are expected to be more
susceptible to air pollution exposure than “healthy” individuals and thus, to465
greatly benefit from pollution decrement.
The distributions of the expected QALY gain and total health care resource
impact of the intervention scaled to each target population are provided in
Appendix B.
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Figure 2: Intervention’s average quality-adjusted life day gain (A) and health care cost impact
(B) per person.
470
3.3. Avoided cases of adverse endpoints/cohort and life expectancy gain/person
The cumulative numbers of cases of CHD, COPD and lung cancer avoided
over the remaining lifetime of individuals in each age and gender-specific cohorts
(see section 2.4.2) is provided in Appendix C, alongside the expected gain in475
life expectancy per person. A 40 year-old person living in England and Wales
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is expected to gain about 23 days of life expectancy for a 1µg/m3 decrement
in PM2.5 concentrations. This is in line with Pascal et al. (2013)’s results for
London. The authors reported a 2.5 months gain/person aged 30 for a decrement
in PM2.5 concentrations by 3.1µg/m
3, which is roughly equivalent (see section480
2.3.3) to a gain of 24.2 life day/person for △PM2.5 = −1µg/m
3. 5
3.4. Results sensitivity to discount rate and cessation lag
485
Two scenarios of staged-discounting, based on recommendations from the
UK treasury for long-term investments (Lowe, 2008) were evaluated against the
base scenario, which applies a 3.5% discount rate p.a. Results are provided in
Appendix D. Decreasing the discount rate to 3% p.a. after the first 30 years
would lead to an increase in total net QALY gain at population level by about490
7%, whereas applying a 3% rate p.a. in the first 30 years and a 2.57% rate p.a.
afterwards would boost net QALY gain by about 20%.
The sensitivity of results to cessation lag were evaluated by applying a com-
bination of different lags to the change in health risks, namely: (i) the US EPA
20-year distributed lag (described in section 2.4.1) for the excess risk of death;495
(ii) a 5-year progressive lag for the change in the excess risks of developing CHD
and COPD and (iii) a 20-year progressive lag for the change in the excess risk
of developing lung cancer. Results are provided in Appendix E. This “mixed
lag” was found to have a minor effect on the total net QALY gain at population
level (increase by about 3%).500
5Whilst Pascal et al. (2013) did not apply a cessation lag, the present application of the
US EPA cessation lag to RRE is expected to have a relatively small effect on the health gain
accruing to young individuals since 80% of the risk reduction is assumed to happen after only
5 years since decrement.
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4. Conclusions
This study provides a novel approach to evaluating the public health benefits
of air pollution control on both quality and length of life dimensions that en-505
compasses for the first time: (i) air pollution’s influence on individuals’ quality
of life and life expectancy at baseline and (ii) dynamics in individuals’ levels of
susceptibility to air pollution exposure, as a consequence of a degraded health
condition that may or may not, be related to cumulative air pollution expo-
sure In addition, the proposed approach supports the evaluation of the health510
care resource impact associated with a joint reduction in chronic morbidity and
premature mortality.
A Markov model was developed to follow adult individuals’ health trajecto-
ries over time from the health states “healthy” to “dead”, across three diseases
that represent the body of epidemiological evidence on the cardio-respiratory ef-515
fects of long-term exposure to fine particulate air pollution: chronic obstructive
pulmonary disease, coronary heart disease and lung cancer.
Application of the model provides the first age and gender-specific estimates
of QALY gain from air quality improvement in the UK, alongside an assessment
of health care budget impact. Reducing mean PM2.5 concentrations by 1µg/m
3
520
in London and in England and Wales (i.e. by 7% and 9% respectively) is
expected to yield more than 63,000 and 540,000 QALYs respectively, to adults
aged 40 and above over their remaining lifetime when discounting at 3.5% p.a.
Against expectations, such an intervention is expected to slightly increase
health care costs. Indeed, after the age of 53, the health care savings from525
reducing the probability that individuals develop COPD, CHD or lung cancer
are on average, more than compensated by the costs associated with extending
the lives of those with a chronic cardiac or respiratory condition. Net health
care costs, however, represent less than 4% of total health benefits, assuming
the NHS delivers 1 QALY for every £13,000 it receives. At a WTP value for530
a QALY of £65,000, which is in line with recommendations for the UK, the
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expected discounted monetary benefit of the intervention amounts to £4 billion
in London and £34 billion in England and Wales.
In a context of increasing interest for the chronic morbidity impacts of
long-term air pollution exposure, as exemplified by large-scale epidemiological535
projects such as ESCAPE6 in Europe and MESA Air7 in the US, the proposed
Markov-based approach to fully capture the lifetime impact of chronic air pol-
lution exposure on individuals’ quality and length of life is expected to be of
particular relevance to support air quality targets. The structure of the model
and its thorough use of epidemiological evidence could be easily replicated -540
and extended if evidence linking PM exposure to other chronic health effects
strengthens in the future - to evaluate the QALY gain and health care resource
impacts of air pollution control elsewhere.
The model developed has, nevertheless, a number of limitations, which were
outlined in Table 3. In particular, its parameterisation is relatively complex,545
which may introduce a number of biases. It is therefore worth noting that life-
expectancy results appear in line with previous findings in the health impact
assessment literature (see section 3.3). Although air pollution’s association with
subclinical respiratory symptoms in children is partly captured in the increased
risk of developing COPD later in adulthood, wider benefits to children, espe-550
cially to those suffering from asthma (Peled, 2011), are not taken into account.
Furthermore, quality of life impacts from acute exposure are ignored. The
model also assumes competitive risk between between disease pathways, which
is a simplification of the clinical reality given that COPD is a multi-component
systemic disease that is associated with a greater risk of cardiovascular events555
and lung cancer (GOLD, 2014). Whilst the model accounts for COPD and lung
cancer characteristics in terms of severity levels and survival pattern over time,
the CHD condition was modelled via a single state, which prevented a refined
analysis of impacts. Finally, the model only considered particulate air pollution
6European Study of Cohorts for Air Pollution Effects.
7Multi-Ethnic Study of Atherosclerosis and Air Pollution.
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whilst the benefits from abating other air pollutants, such as nitrogen dioxide,560
may also need to be considered.
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